NYR next safety cohort announcement next week and clearing complete safety by July with AGN coming out with their results at the same time this current market cap prices in nothing. The time for NYR will come.
“At a market capitalization of just $19m NYR appears significantly undervalued relative to its industry peers. A key comparison is Argenica Therapeutics Limited (ASX: AGN), which is at a comparable stage of clinical development yet trades at approximately $95m – five times NYR’s valuation. This valuation gap suggests that the market has not fully recognized NYR’s potential.”
NYR Price at posting:
10.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)